Stool -therapy for inflammatory bowel disease
Not Applicable
Recruiting
- Conditions
- A04.7Enterocolitis due to Clostridium difficile
- Registration Number
- DRKS00006810
- Lead Sponsor
- niversitätsklinik für Gastroenterologie, Hepatologie und Infektiologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
1. Patient information and consent
2. age> 18 years
3. Life expectancy> 6 months
4 Microbiological detection of CDI recurrence after at least an adequate standard antibiotic therapy with vancomycin> 125 mg / 4 times a day> 10 days or metronidazole 400 mg / 3 times a day
5. CDI-proof:
- Diarrhea (> 3 in two consecutive days)
- C. difficile toxin detection in stool
Exclusion Criteria
1. Congenital or acquired immunodeficiency due to prolonged eg
Chemotherapy / drugs (eg, long-term therapy with prednisolone 60 mg)
2. stage HIV AIDS with CD4 cell counts below 250
3. pregnancy / lactation
4. Unstable circulatory condition (catecholamine / Respiratory
insufficiency)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation the willingness of patients to perform a stool therapy by means of questionnaires on day -2 before therapy resp. Days 1, 3, 7, 14, 30, 90 after treatment
- Secondary Outcome Measures
Name Time Method 1. analysis of the molecular and microbiological changes in stool from the receiver (day -2 before therapy; day 14, 30, 90 after treatment)<br>2. influence on the susceptibility to allergies or respiratory function (day -2 before therapy; 30 days after treatment)<br>